New research indicates that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who stop conventional lifestyle programs.
Findings released in a major health publication points out that while obese people can lose about a fifth of their total mass while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Users using such treatments must be cognizant of the potential of quick weight regain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to starting mass in about one and a half years.
Analyzing Therapies
The study, which looked at 37 of trials involving thousands of participants, contrasted the outcomes of the injectable medications with older methods.
The team point out that people who shed pounds through lifestyle changes alone typically experience a slower creep back—around 0.1 kg a month—once they finish.
Understanding the Fast Regain
Doctors suggest the mode of action of the drugs accounts for the accelerated regain.
These medications copy a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels far above than normal might result in the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication leads to hunger is unsuppressed, making binge eating much more probable."
A Lifelong Condition?
The NHS advise the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals argue that, given the high risk of weight regain, the treatment is often ongoing.
This opinion is supported by drug manufacturers, who say that the findings "emphasize the chronic nature of obesity," comparing it to managing conditions like diabetes.
User Accounts
People who have come off the jabs explain a powerful resurgence of cravings.
"It was like something activating and you're instantly starving," said one woman.
This challenge is compounded if users have not adopted sustainable lifestyle or habit modifications during therapy.
Growing Interest
Figures show that millions of adults in the UK have used these injections in the last 12 months, with demand being substantial.
- Adoption is greater among women than males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone cure and maintained weight loss likely depends on ongoing lifestyle support.
